ALX Oncology Statistics
Share Statistics
ALX Oncology has 53.4M
shares outstanding. The number of shares has increased by 2.46%
in one year.
| Shares Outstanding | 53.4M |
| Shares Change (YoY) | 2.46% |
| Shares Change (QoQ) | 1.22% |
| Owned by Institutions (%) | 77.93% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,564 |
| FTD / Avg. Volume | 0.19% |
Short Selling Information
The latest short interest is 6.14M, so 11.5% of the outstanding
shares have been sold short.
| Short Interest | 6.14M |
| Short % of Shares Out | 11.5% |
| Short % of Float | 18.32% |
| Short Ratio (days to cover) | 10.67 |
Valuation Ratios
The PE ratio is -0.65 and the forward
PE ratio is -0.37.
ALX Oncology's PEG ratio is
0.02.
| PE Ratio | -0.65 |
| Forward PE | -0.37 |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | 0.77 |
| P/FCF Ratio | -0.71 |
| PEG Ratio | 0.02 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for ALX Oncology.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.26,
with a Debt / Equity ratio of 0.
| Current Ratio | 7.26 |
| Quick Ratio | 7.26 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -82.4 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,685,625 |
| Employee Count | 80 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -96.93% in the
last 52 weeks. The beta is 1.2, so ALX Oncology's
price volatility has been higher than the market average.
| Beta | 1.2 |
| 52-Week Price Change | -96.93% |
| 50-Day Moving Average | 0.75 |
| 200-Day Moving Average | 1.78 |
| Relative Strength Index (RSI) | 38.15 |
| Average Volume (20 Days) | 830,006 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -142.47M |
| Net Income | -134.85M |
| EBITDA | -132.25M |
| EBIT | -133.12M |
| Earnings Per Share (EPS) | -2.58 |
Full Income StatementBalance Sheet
The company has 17.57M in cash and 435K in
debt, giving a net cash position of 17.13M.
| Cash & Cash Equivalents | 17.57M |
| Total Debt | 435K |
| Net Cash | 17.13M |
| Retained Earnings | -621.12M |
| Total Assets | 147.78M |
| Working Capital | 115.85M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -121.91M
and capital expenditures -447K, giving a free cash flow of -122.36M.
| Operating Cash Flow | -121.91M |
| Capital Expenditures | -447K |
| Free Cash Flow | -122.36M |
| FCF Per Share | -2.35 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
